Floatz logo

Cytosin-Arabinosid

Atypical Teratoid Rhabdoid Tumor

Medical University of ViennaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Atypical Teratoid Rhabdoid Tumor cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2B
Dfn-15
Medical University of Vienna
Phase 2CCC
Cyclophosphamide
Medical University of Vienna
Phase 2CCC
Fenofibric Acid
Medical University of Vienna
Phase 2CCC
ETOPOSIDE
Medical University of Vienna
Phase 2CCC

View all 38 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →